Yuhong ZHOU (Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China)
【Abstract】 Bone and soft tissue sarcoma is a highly heterogeneous mesophyllogenic malignancy with complex biological behavior and molecular genetics. Although chemotherapy is the main treatment for advanced or metastatic sarcoma, the efficacy is not ideal. In recent years, with the deepening of basic research, gene sequencing and drug research and development, the efficacy of a variety of targeted drugs has been verified to varying degrees in clinical trials and practices of bone and soft tissue tumors, and some new drugs have been approved for indications or entered priority approval. These drugs may change our current and future clinical practice.
【Keywords】Sarcoma; targeted therapy; new drugs
Cite this article:
ZHOU Yuhong. Research Progress on New Drugs for Targeted Therapy for Sarcoma[J]. Electronic Journal of Comprehensive Oncology Treatment,2021,7(4):1-7.
Song Zhengqing, Zhou Yuhong (Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032)
【Abstract】 Soft tissue sarcoma (STS) is a group of complex and highly heterogeneous mesophyllogenous malignancies, and surgery is its main treatment. Although chemotherapy is a palliative first-line treatment option for patients with recurrent metastatic STS, its efficacy is limited. In recent years, immunotherapy has been widely explored in STS, and this paper will sort out the immunological characteristics of STS, as well as the application of new immunotherapy drugs and technologies such as immune checkpoint inhibitors, adoptive cell therapy, and tumor vaccines in STS.
Keywords: soft tissue sarcoma; immunotherapy; immune checkpoint inhibitors; adoptive cell therapy; tumor vaccines
SONG Zhengqing,ZHOU Yuhong. Advances in immunotherapy for soft tissue sarcoma[J]. Electronic Journal of Comprehensive Oncology Treatment,2021,7(4):8-12.
Mengmeng Liu, Xiuxia Lu, Jing Yang, Bushu Xu, Xing Zhang (Department of Melanoma and Sarcoma, Center for Cancer Prevention and Control, Sun Yat-sen University, Guangzhou 510060, China)
【Abstract】 Soft tissue sarcomas (STS) is a group of rare malignant tumors originating from mesophyll tissue, which has a high degree of malignancy and a wide range of pathological subtypes. At present, the main treatment methods of STS include surgery, radiotherapy and chemotherapy, but the efficacy of these traditional treatment methods for advanced and recurrent patients is not ideal. In recent years, with the continuous development of gene sequencing technology, key signaling pathways and drug action targets have been discovered in the development of STS. Novel targeted drugs targeting different pathways and specific targets have also been shown to have significant clinical efficacy, providing more treatment options for STS patients who cannot tolerate surgery and chemotherapy at an advanced stage. This paper briefly describes the research progress of targeted therapy drugs for STS in recent years.
【Keywords】Soft tissue sarcoma; targeted therapy; anti-angiogenesis therapy
Liu Mengmeng,Lu Xiuxia,Yang Jing,et al. Research Progress on Targeted Therapeutic Drugs for Soft Tissue Sarcoma[J]. Electronic Journal of Comprehensive Oncology Treatment,2021,7(4):13-18.
Kai Tian, Yafei Jiang, Yingqi Hua(Department of Orthopedics, First People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Institute of Bone Oncology, Shanghai 200080, China)
【Abstract】 Second-generation sequencing is a technology that can achieve rapid high-throughput sequencing, and commonly used second-generation sequencing techniques include whole exome sequencing, whole genome sequencing, and RNA sequencing. In the field of bone and soft tissue tumors, the use of second-generation sequencing can not only assist in the diagnosis of tumor types that are difficult to distinguish by conventional diagnostic methods in the clinic, but also discover some important tumor driver genes and mutations through sequencing, thus helping to achieve precision treatment. This paper mainly elaborates on the commonly used technologies and characteristics of second-generation sequencing, and reviews the application and research progress of second-generation sequencing techniques in bone and soft tissue tumors.
【Keywords】Second-generation sequencing; bone and soft tissue tumors; auxiliary diagnosis; targeted therapy
TIAN Kai,JIANG Yafei,HUA Yingqi. Application of Second-Generation Sequencing in Bone and Soft Tissue Tumors and Its Research Progress[J]. Electronic Journal of Comprehensive Oncology Treatment,2021,7(4):19-24.
Yuan Li, Qiming Xu, Hairong Xu, Xiaohui Niu (Department of Orthopaedic Oncology, Beijing Jishuitan Hospital, Beijing 100035)
【Abstract】 Giant cell tumor of bone is a primary borderline bone tumor with diverse biological characteristics, which is more likely to occur at the epiphyseal end of long bone, and some have strong invasiveness and high recurrence rate. The exact pathogenesis of giant cell tumor osteoporosis is unclear and is characterized by clinical symptoms caused by osteolysis. Its treatment strategy is mainly surgical treatment, supplemented by radiotherapy, embolism and drug therapy. Drug treatment of osteocytoma mainly includes interferons with anti-angiogenic effects, bisphosphonates that inhibit osteoclasts and lead to bone resorption, and diszylammab, which can block osteoclast maturation and inhibit their osteolytic. Interferon can achieve certain efficacy in the treatment of osteoglobus cell tumor, but the literature is retrospective case analysis, the control group is lacking, and the level of evidence is not high. At present, bisphosphonates are mainly used for osteoglobusomas in the sacrum, spine and pelvic areas, including patients with local treatment difficulties, high intraoperative bleeding risk, and high recurrence rate. However, due to the lack of sufficient evidence in clinical trials, its use time limit, adverse reactions, etc. are also limited to personal experience. In recent years, diszumab has been used in the drug treatment of osteospoma and has shown excellent therapeutic effects, with a tendency to gradually replace bisphosphonates. Pharmacotherapy is effective in reducing recurrence of giant cell tumors of bone and treating giant cell tumors of bone that are not resectable or metastatic.
【Keywords】Giant cell tumor of bone; interferon; bisphosphonate
LI Yuan,XU Qiming,XU Hairong,et al. Drug therapy for osteoma before molecularly targeted therapy[J]. Electronic Journal of Comprehensive Oncology Treatment,2021,7(4):25-30.